Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | USP14 | P54578 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037652 | 0.91 | BRD4 (0.38) | PARP1PARP2SIGMAR1NR1H2 | |
| SCHEMBL3038085 | 0.91 | KDM4E (0.37) | PARP1PARP2SIGMAR1NR1H2 | |
| SCHEMBL3044252 | 0.91 | BRD4 (0.36) | PARP1PARP2SIGMAR1NR1H2 | |
| SCHEMBL3042114 | 0.89 | SMN1; SMN2 (0.39) | PARP1PARP2MCHR1MEN1KMT2A | |
| SCHEMBL3043652 | 0.89 | HSP90AA1 (0.37) | PARP1PARP2SIGMAR1NR1H2 | |
| SCHEMBL3047029 | 0.89 | NR1H2 (0.37) | PARP1NR1H2 | |
| SCHEMBL3048885 | 0.89 | GPR119 (0.37) | PARP1PARP2SIGMAR1NR1H2 | |
| SCHEMBL3047413 | 0.88 | NR1H2 (0.36) | NR1H2 | |
| SCHEMBL3047734 | 0.88 | VEGFA (0.40) | NSD2NR1H2 | |
| SCHEMBL5048301 | 0.87 | BRD4 (0.37) | PARP1PARP2MEN1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | PARP1 2892/4885PARP2 3595/4885AKT1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.